Citius pharmaceuticals, inc. reports fiscal second quarter 2024 financial results and provides business update

Mino-lok data analysis on track with topline results anticipated this quarter lymphir biologics license application accepted with pdufa target action date set for august 13, 2024 cranford, n.j. , may 14, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal second quarter 2024 ended march 31, 2024.
CTXR Ratings Summary
CTXR Quant Ranking